

Rory J Mccrimmon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4290359/publications.pdf>

Version: 2024-02-01

152
papers

11,509
citations

43973

48
h-index

31759

101
g-index

175
all docs

175
docs citations

175
times ranked

13185
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of hypoglycaemia on quality of life among adults with type 1 diabetes: Results from "YourSAY: Hypoglycaemia". Journal of Diabetes and Its Complications, 2023, 37, 108232.	1.2	5
2	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. Diabetologia, 2022, 65, 159-172.	2.9	12
3	Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study. Diabetes Care, 2022, 45, 83-91.	4.3	36
4	Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application. BMJ Open, 2022, 12, e051651.	0.8	13
5	Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 1360-1369.	2.2	28
6	Central deficiency of IL-6Ra in mice impairs glucose-stimulated insulin secretion. Molecular Metabolism, 2022, 61, 101488.	3.0	2
7	Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nature Medicine, 2022, 28, 982-988.	15.2	48
8	Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK. Diabetes Therapy, 2022, , .	1.2	3
9	HypoMETRICS: Hypoglycaemia Measurement, Thresholds and Impact "A multi-country clinical study to define the optimal threshold and duration of sensor-detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocol. Diabetic Medicine, 2022, 39, .	1.2	11
10	Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Subanalyse der SoliMix-Studie bei Teilnehmern in Europa. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
11	Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Nächtliche Hypoglykämien in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
12	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Bessere klinische Ergebnisse mit iGlarLixi vs. BIAsp 30 in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
13	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Hypoglykämien als Funktion des HbA1c in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
14	Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes. JACC: Cardiovascular Imaging, 2021, 14, 503-504.	2.3	9
15	High-intensity training as a novel treatment for impaired awareness of hypoglycaemia in type 1 diabetes [HIT4HYPOS]: Protocol for a randomized parallel-group study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00166.	1.0	3
16	Hyperinsulinaemic "hypoglycaemic glucose clamps in human research: a systematic review of the literature. Diabetologia, 2021, 64, 727-736.	2.9	7
17	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology, the, 2021, 9, 82-93.	5.5	251
18	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia, 2021, 64, 1309-1319.	2.9	5

#	ARTICLE	IF	CITATIONS
19	The suitability of patient-reported outcome measures used to assess the impact of hypoglycaemia on quality of life in people with diabetes: a systematic review using COSMIN methods. <i>Diabetologia</i> , 2021, 64, 1213-1225.	2.9	12
20	Cold-induced dishabituation in rodents exposed to recurrent hypoglycaemia. <i>Diabetologia</i> , 2021, 64, 1436-1441.	2.9	4
21	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. <i>Diabetologia</i> , 2021, 64, 1320-1331.	2.9	19
22	Consequences of recurrent hypoglycaemia on brain function in diabetes. <i>Diabetologia</i> , 2021, 64, 971-977.	2.9	32
23	Advancing therapy with <i>iGlarLixi</i> versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the <i>SoliMix</i> randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1221-1231.	2.2	19
24	Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With <i>iGlarLixi</i> Versus Premix BIAsp 30 in the <i>SoliMix</i> Randomized Controlled Trial. <i>Diabetes Care</i> , 2021, 44, 2361-2370.	4.3	28
25	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. <i>Diabetes Care</i> , 2021, 44, 2010-2017.	4.3	8
26	Adipocyte integrin-linked kinase plays a key role in the development of diet-induced adipose insulin resistance in male mice. <i>Molecular Metabolism</i> , 2021, 49, 101197.	3.0	14
27	The genetic association of the transcription factor NPAT with glycemic response to metformin involves regulation of fuel selection. <i>PLoS ONE</i> , 2021, 16, e0253533.	1.1	0
28	Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis. <i>Journal of Biological Chemistry</i> , 2021, 296, 100439.	1.6	28
29	Clinical approaches to treat impaired awareness of hypoglycaemia. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110002.	1.4	16
30	Cost-Effectiveness of <i>iGlarLixi</i> Versus <i>iDegLira</i> in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy. <i>Diabetes Therapy</i> , 2021, 12, 3231-3241.	1.2	9
31	Cost-Effectiveness of <i>iGlarLixi</i> in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK. <i>Diabetes Therapy</i> , 2021, 12, 3217-3230.	1.2	8
32	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. <i>Diabetologia</i> , 2020, 63, 473-485.	2.9	37
33	Reducing Glut2 throughout the body does not result in cognitive behaviour differences in aged male mice. <i>BMC Research Notes</i> , 2020, 13, 438.	0.6	2
34	Socioeconomic status and mortality in people with type 1 diabetes in Scotland 2006-2015: a retrospective cohort study. <i>Diabetic Medicine</i> , 2020, 37, 2081-2088.	1.2	14
35	Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. <i>Circulation</i> , 2020, 142, 1713-1724.	1.6	144
36	Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. <i>Diabetes Therapy</i> , 2020, 11, 2629-2645.	1.2	14

#	ARTICLE	IF	CITATIONS
37	Real-time Continuous Glucose Monitoring During a Hyperinsulinemic-Hypoglycemic Clamp Significantly Underestimates the Degree of Hypoglycemia. <i>Diabetes Care</i> , 2020, 43, e142-e143.	4.3	11
38	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004-2017. <i>Diabetologia</i> , 2020, 63, 1626-1636.	2.9	6
39	Experimental Models of Impaired Hypoglycaemia-Associated Counter-Regulation. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 691-703.	3.1	11
40	Inhibition of NFAT Signaling Restores Microvascular Endothelial Function in Diabetic Mice. <i>Diabetes</i> , 2020, 69, 424-435.	0.3	17
41	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. <i>European Heart Journal</i> , 2020, 41, 3421-3432.	1.0	138
42	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology's Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq0 0 0 TgBT /Overlock 10	4.3	13
43	A randomised controlled study of high intensity exercise as a dishabituating stimulus to improve hypoglycaemia awareness in people with type 1 diabetes: a proof-of-concept study. <i>Diabetologia</i> , 2020, 63, 853-863.	2.9	13
44	Reducing the burden of hypoglycaemia in people with diabetes through increased understanding: design of the Hypoglycaemia REdefining SOLutions for better lIVes (Hypo-RESOLVE) project. <i>Diabetic Medicine</i> , 2020, 37, 1066-1073.	1.2	27
45	Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. <i>ESC Heart Failure</i> , 2020, 7, 1168-1177.	1.4	14
46	960-P: Characteristics of U.S. Patients with Type 2 Diabetes Prescribed GLP-1RA+SGLT2i in Combination during 2018. <i>Diabetes</i> , 2020, 69, 960-P.	0.3	0
47	Investigating the Relationship Between Type 2 Diabetes and Dementia Using Electronic Medical Records in the GoDARTS Bioresource. <i>Diabetes Care</i> , 2019, 42, 1973-1980.	4.3	14
48	CD44 contributes to hyaluronan-mediated insulin resistance in skeletal muscle of high-fat-fed C57BL/6 mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E973-E983.	1.8	22
49	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 834-844.	5.5	149
50	Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1967-1972.	2.2	14
51	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 121-130.	6.3	1,625
52	Glycaemic control trends in people with type 1 diabetes in Scotland 2004-2016. <i>Diabetologia</i> , 2019, 62, 1375-1384.	2.9	45
53	Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 273-285.	2.4	26
54	Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1187-1199.	1.8	51

#	ARTICLE	IF	CITATIONS
55	Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 385-396.	5.5	298
56	Loss of CRMP2 O-GlcNAcylation leads to reduced novel object recognition performance in mice. <i>Open Biology</i> , 2019, 9, 190192.	1.5	17
57	In-vivo correlations between skin metabolic oscillations and vasomotion in wild-type mice and in a model of oxidative stress. <i>Scientific Reports</i> , 2019, 9, 186.	1.6	9
58	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. <i>Diabetologia</i> , 2019, 62, 621-632.	2.9	33
59	Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. <i>Diabetic Medicine</i> , 2019, 36, 718-725.	1.2	46
60	113-OR: ADA Presidents' Select Abstract: Dishabituation with High Intensity Exercise Improves Epinephrine Response and Symptomatic Awareness to Hypoglycemia in People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia. <i>Diabetes</i> , 2019, 68, .	0.3	2
61	Impaired hypoglycaemia awareness in type 1 diabetes: lessons from the lab. <i>Diabetologia</i> , 2018, 61, 743-750.	2.9	36
62	Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 367-398.	2.3	154
63	Bace1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice. <i>Scientific Reports</i> , 2018, 8, 55.	1.6	29
64	Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. <i>Diabetes Therapy</i> , 2018, 9, 1347-1358.	1.2	47
65	Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004-2013. <i>Diabetic Medicine</i> , 2018, 35, 99-106.	1.2	19
66	Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012-2014): a population-based observational study. <i>Diabetologia</i> , 2018, 61, 108-116.	2.9	42
67	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. <i>Diabetes Care</i> , 2018, 41, 341-347.	4.3	92
68	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018, 41, 2552-2559.	4.3	177
69	Amputation-free survival in 17,353 people at high risk for foot ulceration in diabetes: a national observational study. <i>Diabetologia</i> , 2018, 61, 2590-2597.	2.9	55
70	SGLT inhibitor adjunct therapy in type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 2126-2133.	2.9	68
71	Exercise management in type 1 diabetes: a consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 377-390.	5.5	588
72	AMP-activated protein kinase (AMPK) activator A-769662 increases intracellular calcium and ATP release from astrocytes in an AMPK-independent manner. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 997-1005.	2.2	23

#	ARTICLE	IF	CITATIONS
73	High-Intensity Exercise as a Dishabituating Stimulus Restores Counterregulatory Responses in Recurrently Hypoglycemic Rodents. <i>Diabetes</i> , 2017, 66, 1696-1702.	0.3	20
74	Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. <i>BMC Nephrology</i> , 2017, 18, 163.	0.8	63
75	Oleate induces K ATP channel-dependent hyperpolarization in mouse hypothalamic glucose-excited neurons without altering cellular energy charge. <i>Neuroscience</i> , 2017, 346, 29-42.	1.1	9
76	Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2017, 60, 3-6.	2.9	99
77	Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. <i>BMJ Open</i> , 2017, 7, e018097.	0.8	38
78	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 864-876.	5.5	244
79	RD Lawrence Lecture 2015 Old habits are hard to break: lessons from the study of hypoglycaemia. <i>Diabetic Medicine</i> , 2017, 34, 148-155.	1.2	9
80	Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 229.	0.7	25
81	Saxagliptin co-therapy in C-peptide negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia. <i>Diabetic Medicine</i> , 2016, 33, 1283-1290.	1.2	7
82	Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study. <i>BMJ Open</i> , 2016, 6, e010836.	0.8	41
83	Chronic Activation of β 2 AMPK Induces Obesity and Reduces β 2 Cell Function. <i>Cell Metabolism</i> , 2016, 23, 821-836.	7.2	87
84	Chronic exposure to KATP channel openers results in attenuated glucose sensing in hypothalamic GT1-7 neurons. <i>Neuropharmacology</i> , 2016, 111, 212-222.	2.0	4
85	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. <i>Diabetologia</i> , 2016, 59, 2106-2113.	2.9	71
86	Testing the accelerator hypothesis: a new approach to type 1 diabetes prevention (adAPT 1). <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 3-5.	2.2	13
87	Nrf2-Mediated Neuroprotection Against Recurrent Hypoglycemia Is Insufficient to Prevent Cognitive Impairment in a Rodent Model of Type 1 Diabetes. <i>Diabetes</i> , 2016, 65, 3151-3160.	0.3	34
88	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 37.	3.8	454
89	Diazoxide Improves Hormonal Counterregulatory Responses to Acute Hypoglycemia in Long-standing Type 1 Diabetes. <i>Diabetes</i> , 2015, 64, 2234-2241.	0.3	19
90	Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. <i>Diabetologia</i> , 2015, 58, 716-725.	2.9	26

#	ARTICLE	IF	CITATIONS
91	The Scylla and Charybdis of glucose control in childhood type 1 diabetes?. <i>Pediatric Diabetes</i> , 2015, 16, 235-241.	1.2	16
92	Susceptibility of Nrf2-Null Mice to Steatohepatitis and Cirrhosis upon Consumption of a High-Fat Diet Is Associated with Oxidative Stress, Perturbation of the Unfolded Protein Response, and Disturbance in the Expression of Metabolic Enzymes but Not with Insulin Resistance. <i>Molecular and Cellular Biology</i> , 2014, 34, 3305-3320.	1.1	187
93	AMPK modulates glucose-sensing in insulin-secreting cells by altered phosphotransfer to KATP channels. <i>Journal of Bioenergetics and Biomembranes</i> , 2013, 45, 229-241.	1.0	18
94	Continuous hypothalamic KATP activation blunts glucose counter-regulation in vivo in rats and suppresses KATP conductance in vitro. <i>Diabetologia</i> , 2013, 56, 2088-2092.	2.9	3
95	Potential role of non- β insulin adjunct therapy in Type 1 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 179-188.	1.2	39
96	Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: A model for weight gain with intensive insulin therapy. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E131-E138.	1.8	25
97	An interesting case of new-onset ketosis-prone diabetes in a Scottish teaching hospital. <i>British Journal of Diabetes and Vascular Disease</i> , 2013, 13, 265-268.	0.6	0
98	Hypothalamic Fkbp51 is induced by fasting, and elevated hypothalamic expression promotes obese phenotypes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 302, E987-E991.	1.8	25
99	Update in the CNS Response to Hypoglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1-8.	1.8	83
100	The physiology and pathophysiology of the neural control of the counterregulatory response. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2012, 302, R215-R223.	0.9	52
101	Diabetes and cognitive dysfunction. <i>Lancet</i> , 2012, 379, 2291-2299.	6.3	722
102	Hypoglycaemia: Exercise for the Brain?. <i>Journal of Neuroendocrinology</i> , 2012, 24, 1365-1366.	1.2	0
103	Mouse hypothalamic GT1-7 cells demonstrate AMPK-dependent intrinsic glucose-sensing behaviour. <i>Diabetologia</i> , 2012, 55, 2432-2444.	2.9	57
104	3. Cerebral Adaptation to Recurrent Hypoglycemia. <i>Translational Endocrinology & Metabolism</i> , 2012, , 89-114.	0.2	6
105	The Response to Hypoglycemia: A Role for the Opioid System?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3357-3359.	1.8	6
106	An Estimate of Lifetime Cognitive Change and Its Relationship with Diabetes Health in Older Adults with Type 1 Diabetes: Preliminary Results. <i>Behavioural Neurology</i> , 2010, 23, 165-167.	1.1	7
107	Hypoglycemia in Type 1 Diabetes. <i>Diabetes</i> , 2010, 59, 2333-2339.	0.3	161
108	<i>Radix astragalii</i> (Huangqi) as a Treatment for Defective Hypoglycemia Counterregulation in Diabetes. <i>The American Journal of Chinese Medicine</i> , 2010, 38, 1027-1038.	1.5	18

#	ARTICLE	IF	CITATIONS
109	Ventromedial Hypothalamic Nitric Oxide Production Is Necessary for Hypoglycemia Detection and Counterregulation. <i>Diabetes</i> , 2010, 59, 519-528.	0.3	95
110	Influence of Insulin in the Ventromedial Hypothalamus on Pancreatic Glucagon Secretion In Vivo. <i>Diabetes</i> , 2010, 59, 1521-1527.	0.3	80
111	The Medial Amygdalar Nucleus: A Novel Glucose-Sensing Region That Modulates the Counterregulatory Response to Hypoglycemia. <i>Diabetes</i> , 2010, 59, 2646-2652.	0.3	60
112	Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. <i>Neurobiology of Learning and Memory</i> , 2010, 93, 546-553.	1.0	319
113	Glucose Sensing During Hypoglycemia: Lessons From the Lab. <i>Diabetes Care</i> , 2009, 32, 1357-1363.	4.3	37
114	Medium-Chain Fatty Acids Improve Cognitive Function in Intensively Treated Type 1 Diabetic Patients and Support In Vitro Synaptic Transmission During Acute Hypoglycemia. <i>Diabetes</i> , 2009, 58, 1237-1244.	0.3	128
115	Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 296, R1702-R1708.	0.9	41
116	The mechanisms that underlie glucose sensing during hypoglycaemia in diabetes. <i>Diabetic Medicine</i> , 2008, 25, 513-522.	1.2	58
117	Increased GABAergic Tone in the Ventromedial Hypothalamus Contributes to Suppression of Counterregulatory Responses After Antecedent Hypoglycemia. <i>Diabetes</i> , 2008, 57, 1363-1370.	0.3	93
118	Amplified Hormonal Counterregulatory Responses to Hypoglycemia in Rats After Systemic Delivery of a SUR-1-Selective K ⁺ Channel Opener?. <i>Diabetes</i> , 2008, 57, 3327-3334.	0.3	15
119	Key Role for AMP-Activated Protein Kinase in the Ventromedial Hypothalamus in Regulating Counterregulatory Hormone Responses to Acute Hypoglycemia. <i>Diabetes</i> , 2008, 57, 444-450.	0.3	152
120	Type 1 corticotropin-releasing factor receptors in the ventromedial hypothalamus promote hypoglycemia-induced hormonal counterregulation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E705-E712.	1.8	30
121	Synaptic Glutamate Release by Ventromedial Hypothalamic Neurons Is Part of the Neurocircuitry that Prevents Hypoglycemia. <i>Cell Metabolism</i> , 2007, 5, 383-393.	7.2	358
122	Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways. <i>Cell Metabolism</i> , 2007, 6, 398-405.	7.2	200
123	5'AMP-activated protein kinase ? deficiency enhances stress-induced apoptosis in BHK and PC12 cells. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 286-298.	1.6	22
124	Cognitive and Neural Hippocampal Effects of Long-Term Moderate Recurrent Hypoglycemia. <i>Diabetes</i> , 2006, 55, 1088-1095.	0.3	92
125	Blockade of GABAA Receptors in the Ventromedial Hypothalamus Further Stimulates Glucagon and Sympathoadrenal but Not the Hypothalamo-Pituitary-Adrenal Response to Hypoglycemia. <i>Diabetes</i> , 2006, 55, 1080-1087.	0.3	107
126	Activation of AMP-Activated Protein Kinase Within the Ventromedial Hypothalamus Amplifies Counterregulatory Hormone Responses in Rats With Defective Counterregulation. <i>Diabetes</i> , 2006, 55, 1755-1760.	0.3	107

#	ARTICLE	IF	CITATIONS
127	Antecedent Hypercortisolemia Is Not Primarily Responsible for Generating Hypoglycemia-Associated Autonomic Failure. <i>Diabetes</i> , 2006, 55, 1121-1126.	0.3	35
128	Corticotrophin-releasing factor receptors within the ventromedial hypothalamus regulate hypoglycemia- induced hormonal counterregulation. <i>Journal of Clinical Investigation</i> , 2006, 116, 1723-1730.	3.9	81
129	Activation of ATP-Sensitive K ⁺ Channels in the Ventromedial Hypothalamus Amplifies Counterregulatory Hormone Responses to Hypoglycemia in Normal and Recurrently Hypoglycemic Rats. <i>Diabetes</i> , 2005, 54, 3169-3174.	0.3	103
130	Influence of an Early-Onset Age of Type 1 Diabetes on Cerebral Structure and Cognitive Function. <i>Diabetes Care</i> , 2005, 28, 1431-1437.	4.3	208
131	Potential Role for AMP-Activated Protein Kinase in Hypoglycemia Sensing in the Ventromedial Hypothalamus. <i>Diabetes</i> , 2004, 53, 1953-1958.	0.3	142
132	Hypothalamic ATP-sensitive K ⁺ Channels Play a Key Role in Sensing Hypoglycemia and Triggering Counterregulatory Epinephrine and Glucagon Responses. <i>Diabetes</i> , 2004, 53, 2542-2551.	0.3	145
133	Effects of acute hypoglycaemia on auditory information processing in adults with Type I diabetes. <i>Diabetologia</i> , 2003, 46, 97-105.	2.9	35
134	Effects of recurrent antecedent hypoglycaemia and chronic hyperglycaemia on brainstem extra-cellular glucose concentrations during acute hypoglycaemia in conscious diabetic BB rats. <i>Diabetologia</i> , 2003, 46, 1658-1661.	2.9	15
135	Symptoms reported during experimental hypoglycaemia: effect of method of induction of hypoglycaemia and of diabetes per se. <i>Diabetic Medicine</i> , 2003, 20, 507-509.	1.2	13
136	Cognitive Ability and Brain Structure in Type 1 Diabetes: Relation to Microangiopathy and Preceding Severe Hypoglycemia. <i>Diabetes</i> , 2003, 52, 149-156.	0.3	270
137	AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E1076-E1083.	1.8	41
138	Effect of pancreatic transplantation on counterregulatory hormonal responses to hypoglycaemia. <i>Acta Diabetologica</i> , 1999, 36, 11-20.	1.2	6
139	Appraisal of Mood and Personality During Hypoglycaemia in Human Subjects. <i>Physiology and Behavior</i> , 1999, 67, 27-33.	1.0	53
140	Anger State During Acute Insulin-Induced Hypoglycaemia. <i>Physiology and Behavior</i> , 1999, 67, 35-39.	1.0	27
141	Perceived symptoms of hypoglycaemia in elderly Type 2 diabetic patients treated with insulin. , 1998, 15, 398-401.		121
142	Hypoglycaemic symptoms reported by children with Type 1 diabetes mellitus and by their parents. , 1998, 15, 836-843.		20
143	Effect of acute hypoglycemia on visual information processing in adults with type 1 diabetes mellitus. <i>Physiology and Behavior</i> , 1998, 64, 653-660.	1.0	76
144	Visual information processing and intelligence. <i>Intelligence</i> , 1997, 24, 461-479.	1.6	28

#	ARTICLE	IF	CITATIONS
145	Auditory information processing during acute insulin-induced hypoglycaemia in non-diabetic human subjects. <i>Neuropsychologia</i> , 1997, 35, 1547-1553.	0.7	33
146	Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the analogue Lispro human insulin. , 1997, 14, 929-936.		22
147	Visual information processing during controlled hypoglycaemia in humans. <i>Brain</i> , 1996, 119, 1277-1287.	3.7	92
148	Symptoms of Hypoglycemia in Children With IDDM. <i>Diabetes Care</i> , 1995, 18, 858-861.	4.3	63
149	Frequency of Thyroid Dysfunction in Diabetic Patients: Value of Annual Screening. <i>Diabetic Medicine</i> , 1995, 12, 622-627.	1.2	312
150	Hypoglycaemia, the most feared complication of insulin therapy. <i>Diab�te & M�tabolisme</i> , 1994, 20, 503-12.	0.3	43
151	Dominantly inherited syndrome comprising partially absent eye muscles, hydrocephaly, skeletal abnormalities, and a distinctive facial phenotype. <i>American Journal of Medical Genetics Part A</i> , 1991, 40, 417-420.	2.4	18
152	Nrf2 mediated protection against hypoglycaemia induced cognitive deficits in type 1 diabetes. <i>Endocrine Abstracts</i> , 0, , .	0.0	0